Published in final edited form as:

Am J Obstet Gynecol. 2017 May ; 216(5): 500.e1–500.e11. doi:10.1016/j.ajog.2016.12.177.

Periprocedural Outcomes Comparing Fibroid Embolization and Focused Ultrasound: a Randomized Controlled Trial and Comprehensive Cohort Analysis

Emily P. Barnard, DO, Ahmed M. Abdelmagied, MB, BCh, Lisa E. Vaughan, MS, Amy L. Weaver, MS, Shannon K. Laughlin-Tommaso, MD, Gina K. Hesley, MD, David A. Woodrum, MD, PhD, Vanessa L. Jacoby, MD, MAS, Maureen P. Kohi, MD, Thomas M. Price, MD, Angel Nieves, MD, PhD, Michael J. Miller, MD, Bijan J. Borah, PhD, Krzysztof R. Gorny, PhD, Phyllis C. Leppert, MD, PhD, Lisa G. Peterson, RN, and Elizabeth A. Stewart, MD

Department of Obstetrics and Gynecology (Drs Barnard, Abdelmagied, Laughlin-Tommaso, Borah, and Stewart), Division of Biomedical Statistics and Informatics (Mss Vaughan and Weaver), Department of Radiology (Drs Hesley, Woodrum, and Gorny), Division of Health Care Policy and Research (Dr Borah), and Department of Research Administration (Ms Peterson), Mayo Clinic, Rochester, Minnesota; Obstetrics, Gynecology, and Reproductive Sciences (Dr Jacoby) and Radiology and Biomedical Imaging (Dr Kohi), University of California, San Francisco, San Francisco, California; Obstetrics and Gynecology (Drs Price, Nieves, and Leppert) and Department of Radiology (Dr Miller), Duke University, Durham, North Carolina; and Department of Obstetrics and Gynecology (Dr Abdelmagied), Women Health Hospital, Assiut University, Assiut, Egypt

Abstract

Background—Uterine fibroids are a common problem for reproductive-aged women, yet little comparative effectiveness research is available to guide treatment choice. Uterine artery embolization and magnetic resonance imaging–guided focused ultrasound surgery are minimally invasive therapies approved by the United States Food and Drug Administration for treating symptomatic uterine fibroids. The Fibroid Interventions: Reducing Symptoms Today and Tomorrow study is the first randomized controlled trial to compare these 2 fibroid treatments. (NCT00995878, clinicaltrials.gov)

Objective—To summarize treatment parameters and compare recovery trajectory and adverse events in the first 6 weeks after treatment.

Study Design—Premenopausal women with symptomatic uterine fibroids seen at 3 US academic medical centers were enrolled in the randomized controlled trial (n=57). Women meeting identical criteria who declined randomization but agreed to study participation were

Reprints: Elizabeth A. Stewart, MD, Department of Obstetrics and Gynecology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, (stewart.elizabeth@mayo.edu).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest: E.P.B., L.E.V., A.L.W., S.K.L.-T., D.A.W., M.P.K., M.J.M., B.J.B., and L.G.P. have nothing to disclose.

enrolled in a nonrandomized parallel cohort (n=34). The 2 treatment groups were analyzed by using a comprehensive cohort design. All women undergoing focused ultrasound and uterine artery embolization received the same postprocedure prescriptions, instructions, and symptom diaries for comparison of recovery in the first 6 weeks. Return to work and normal activities, medication use, symptoms, and adverse events were captured with postprocedure diaries. Data were analyzed using the Wilcoxon rank sum test or χ^2 test. Multivariable regression was used to adjust for baseline pain levels and fibroid load when comparing opioid medication, adverse events, and recovery time between treatment groups because these factors varied at baseline between groups and could affect outcomes. Adverse events were also collected.

Results—Of 83 women in the comprehensive cohort design who underwent treatment, 75 completed postprocedure diaries. Focused ultrasound surgery was a longer procedure than embolization (mean [SD], 405 [146] vs 139 [44] min; $P<.001$). Of women undergoing focused ultrasound (n=43), 23 (53%) underwent 2 treatment days. Immediate self-rated postprocedure pain was higher after uterine artery embolization than focused ultrasound (median [interquartile range], 5 [1–7] vs 1 [1–4]; $P=.002$). Compared with those having focused ultrasound (n=39), women undergoing embolization (n=36) were more likely to use outpatient opioid (75% vs 21%; $P<.001$) and nonsteroidal anti-inflammatory medications (97% vs 67%; $P<.001$) and to have a longer median (interquartile range) recovery time (days off work, 8 [6–14] vs 4 [2–7]; $P<.001$; days until returned to normal, 15 [10–29] vs 10 [10–15]; $P=.02$). There were no significant differences in the incidence or severity of adverse events between treatment arms; 86% (42/49) of adverse events required only observation or nominal treatment, and no events caused permanent sequelae or death. After adjustment for baseline pain and uterine fibroid load, uterine artery embolization was still significantly associated with higher opioid use and longer time to return to work and normal activities ($P<.001$ for each). Results were similar when restricted to the randomized controlled trial.

Conclusions—Women undergoing uterine artery embolization have longer recovery times and use more prescription medications, but women undergoing focused ultrasound have longer treatment times. These findings were independent of baseline pain levels and fibroid load.

Condensation

Women undergoing focused ultrasound had longer procedures, whereas women undergoing uterine artery embolization used more postprocedural pain medications and took longer to resume baseline functioning.

Keywords

focused ultrasound; leiomyoma; randomized controlled trial; uterine artery embolization; uterine fibroid

Introduction

Uterine fibroids (myomas or leiomyomas) are common and debilitating in reproductive-aged women, yet little high-quality evidence exists to guide treatment decisions (1). Most randomized controlled trials (RCTs) of fibroid therapies have been performed outside the

United States (2–10), and those performed in the United States for the related problem of heavy menstrual bleeding have faced recruitment challenges (11–14).

The Fibroid Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT) study is a National Institutes of Health–funded RCT to evaluate the efficacy of 2 minimally invasive fibroid treatments: uterine artery embolization (UAE) and magnetic resonance imaging–guided focused ultrasound surgery (MRgFUS) (NCT00995878, clinicaltrials.gov) (15). The aim of the FIRSTT study is to examine the safety, efficacy, and economics of these therapies and the ovarian reserve after treatment.

In addition to the RCT participants, women who met identical enrollment criteria but declined randomization were recruited into a parallel cohort (PC1). Analysis of FIRSTT trial baseline data showed that using a comprehensive cohort design (CCD), combining the RCT and PC1 participants, yields valid results and provides additional power (16,17). The current report summarizes the treatment parameters, recovery trajectory, and adverse events (AEs) of patients during the first 6 weeks after treatment, using both RCT and CCD analyses.

Materials and Methods

Overview

The design and baseline data from the FIRSTT study have been previously reported (15,16). The Institutional Review Boards at Mayo Clinic, Rochester, Minnesota, Duke University, Durham, North Carolina, and the University of California, San Francisco, approved the same study protocol. Briefly, UAE and MRgFUS were performed according to the clinical standard of care, with follow-up for up to 36 months.

Study Population and Randomization

All participants were premenopausal women with symptomatic uterine fibroids who were not actively seeking pregnancy and had uteri smaller than 20 gestational weeks. Full enrollment criteria have been reported previously (15,16). Enrollment began April 29, 2010, for the RCT, and March 24, 2011, for the PC1 group. All study procedures were performed by August 1, 2014. A study gynecologist screened all participants, and treating physicians at each site were experts in these therapies. Multiple general and disease-specific quality-of-life measures, including the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) instrument, were recorded at baseline (15,18). Randomization was stratified by site and by calculated uterine volume (≥ 700 vs <700 cm³) and performed using a Web-based, dynamic allocation application (19). Neither participants nor investigators were blinded to study assignments.

Standardized Treatment and Recovery Protocols

Both UAE and MRgFUS were performed using standardized protocols. The treating physician captured key treatment variables on the day of treatment, including whether a complete treatment was achieved. This result was not disclosed to the patient. Identical standardized instructions and postprocedural prescriptions were used for both procedures.

UAE Protocol

For UAE, a standardized protocol that allowed for some variation among sites was used, which included moderate sedation and anti-inflammatory and antiemetic agents (20). Prophylactic antibiotics were used at all sites; at 1 site, oral antibiotics were continued for another 5 days.

UAE was performed, along with arteriography to evaluate for collateral ovarian blood supply to the fibroids. Tris-acryl gelatin microspheres (500–700 μm) were used; if necessary, 700–900- μm spheres were also used until near-stasis was achieved. Post procedure, patients were admitted overnight to a hospital-based observation unit.

MRgFUS Protocol

Treatments were performed with a clinical MRgFUS system (ExAblate 2000; InSightec, Haifa, Israel) with moderate conscious sedation (21). T2-weighted magnetic resonance images were acquired, and the sonication plan was developed. Sonication pulse duration was generally 12 to 24 seconds, with an interpulse interval of 45 to 90 seconds to allow for tissue cooling. At the conclusion, gadolinium contrast was administered, and T1-weighted images were acquired for visualization of nonperfused volume (NPV). After MRgFUS treatment, women were typically observed for 1 hour and discharged with an escort. Two sites allowed 2 sequential treatment days.

For both treatment groups, baseline image analysis was performed using Vitrea 3 Software (Vital Images, Inc; Minnetonka, Minnesota). For the MRgFUS group, the NPV ratio (ie, the ratio [%] of NPV to total fibroid load) was analyzed similarly.

Data Safety Monitoring Board

The Data Safety Monitoring Board comprised 2 fibroid experts, 1 gynecologist, and 1 radiologist, in addition to the study statistician (A.L.W.). The National Institutes of Health project officer also reviewed safety-related issues.

Postprocedure Medications and Instructions

For both procedures, women received identical prescriptions and instructions for medication usage; slight variations among sites and modifications were allowed in the case of allergies or known prior medication use. Women were typically provided with a prescription for oxycodone (5 mg, 40 tablets), ibuprofen (600 mg, 30 tablets, 2 refills), ondansetron (4 mg, 6 tablets, 1 refill), and docusate sodium (100 mg, 10 tablets, 2 refills). Women also received written instructions that acetaminophen could be taken with the study medications. Medications taken during the study period were to be recorded in the study diaries. The postoperative instructions outlined the goal that pain should be as close as possible to 0 on a 10-point pain scale. Contact information for the site investigator and the study coordinator were provided.

Postprocedure Diaries

Women received 3 single-page color-coded diaries with stamped return envelopes at the time of hospital discharge. Each diary covered 2 weeks of recovery and included a pictorial

representation of a 10-point pain scale. Information recorded in the diaries included medication use, functional status after surgery, bleeding, pain, and common symptoms. The study coordinator called women on the weekday nearest to the date of expected diary completion and reminded them to return their current diary and start the next one.

Adverse Events

Data on AEs were obtained via clinic or hospital notes, review of the diaries, and telephone calls with study staff. Characterization included severity (eg, mild, moderate, or severe) based on the Common Terminology Criteria for Adverse Events. Relatedness to the procedure (eg, definitely, probably, possibly, unlikely, or unrelated) was determined by the site investigator, and the patient's outcome was recorded. We further classified AEs using both the Society of Interventional Radiology (SIR) classification system, which grades events on a scale from A (no therapy, no consequences) to F (death) (22), and the American College of Obstetricians and Gynecologists system, which characterizes morbidity indicators such as fever, hemorrhage, unintended procedures, life-threatening events, and readmission (23).

Data Management and Statistical Analysis

Data were analyzed using both a CCD and an RCT design (16). Demographic and baseline characteristics, day-of-treatment parameters, and postprocedure recovery measures were summarized and reported using standard descriptive statistics: frequency (percentage) for categorical variables and mean (SD) or median (interquartile range [IQR]) for continuous variables. Comparisons between treatment arms (MRgFUS vs UAE) were evaluated using the χ^2 test or Fisher exact test for categorical variables and the 2-sample *t* test or Wilcoxon rank sum test for continuous variables. Because pain and total fibroid load can substantially affect recovery parameters and there was a differential loss of participants in the UAE arm after randomization (16), multivariable regression analysis was used to assess the independent effect of treatment group on posttreatment recovery measures after adjustment for pain levels and total fibroid load at baseline. Adjusted odds ratios were obtained using logistic regression for the rare (<10%) binary outcome (*AE SIR class C–E*), adjusted risk ratios were obtained using Poisson regression with a robust error variance for the common binary outcomes (*opioid use* and *any AE*), and linear regression was used to estimate the average difference in days for the continuous outcomes (recovery time in days) (24). In these models, logarithmic transformation was applied to the recovery time continuous outcome measures (natural log) and total fibroid load (log base 2) because of the skewed data. Model results were back-transformed to obtain adjusted estimates and confidence intervals in the original scale of the outcome variable. All calculated *P* values were 2-sided, and *P* < .05 was considered statistically significant. Analyses were performed using SAS version 9.3 software (SAS Institute Inc, Cary, North Carolina).

Results

Baseline Demographics

Of 83 women who underwent treatment in the CCD cohort (43 MRgFUS, 40 UAE), 75 completed the postprocedure diaries (Figure). Baseline parameters were similar between

women undergoing UAE and MRgFUS in both the RCT and CCD analysis (Table 1) (16). The remainder of the data presented refer to the CCD cohort, unless otherwise specified. Women in the study were predominantly white and overweight. Calculated median (IQR) uterine volumes were similar between treatment arms (UAE, 540 [382–837] vs MRgFUS, 586 [395–707] cm³). However, women undergoing UAE had a larger mean (SD) fibroid load than women in the MRgFUS group (362.5 [292.3] vs 249.2 [159.9] cm³; $P=.03$), and the number of fibroids larger than 3 cm was higher in women undergoing MRgFUS. Participants in both arms had similar fibroid symptoms and substantially impaired fibroid-specific quality of life based on the UFS-QOL. Baseline pain scores tended to be higher in women undergoing MRgFUS, and the difference in visual analog scale for pain (VAS) scores reached significance in the RCT (MRgFUS, 48.0 [27.0–71.0] vs UAE, 27.0 [5.0–52.0]; $P=.03$) (Table 1).

Day-of-Treatment Parameters

In the UAE group, 36 of the 40 procedures (90%) were done with a unilateral puncture; all were performed in 1 day, with a mean (SD) fluoroscopy time of 42.0 (19.2) minutes (Supplemental Table 1). Total blood loss was minimal, and 100% of the treatments were deemed complete. The majority of the procedures used fentanyl (85%) and midazolam (93%).

Among the 43 women undergoing MRgFUS, 23 (53%) underwent a second day of treatment (Supplemental Table 2). The number of fibroids sonicated ranged from 1 to 9, with 19 patients (44%) having 1 fibroid treated. Mean (SD) NPV ratio was 46.1% (24.8%) (Supplemental Table 2). The treating physician judged that 39 women (91%) had complete MRgFUS treatment. Similar to UAE, most procedures were performed using intravenous opioids (93%) and midazolam (98%).

Women undergoing MRgFUS had significantly lower self-rated postprocedural pain than women undergoing UAE (1.0 [1.0–4.0] vs 4.0 [2.0–6.0]; $P<.001$) (Table 1). All UAE patients remained overnight as inpatients, and all MRgFUS patients were discharged on the day of the procedure.

6-Week Recovery Trajectory

Women undergoing UAE were more likely than the MRgFUS group to use outpatient opioid medication (75% vs 21%; $P<.001$) (Table 2). However, among opioid users, the last day of opioid use occurred later in the MRgFUS group than the UAE group (day 27 [4–41] vs day 3 [2–5]; $P=.03$). In particular, in the RCT group, 2 women who underwent MRgFUS took opioid pain medication for the entire 6-week follow-up period.

Nonsteroidal anti-inflammatory drug use was also higher in UAE patients than MRgFUS patients (97% vs 67%; $P<.001$), although the total days of use did not significantly differ between treatment arms (7 [2–19] vs 9 [6–13] days; $P=.58$). Antiemetic and stool softener use was also significantly more frequent in the UAE patients (both $P<.001$) (Table 2).

Women undergoing the UAE procedure took longer to return to work than did women in the MRgFUS group (8 [6–14] vs 4 [2–7] days; $P<.001$). The day of the week the treatment was

scheduled did not affect this parameter (data not shown). The first day on which participants felt they were “totally back to normal” also occurred later in the UAE group (15 [10–29] vs 10 [10–15] days; $P=.02$). No significant differences were observed in hot flashes and passage of fibroid tissue from the vagina.

Adverse Events

A total of 36 patients (20 MRgFUS, 16 UAE) experienced 49 AEs; rates overall and rates of severe AEs (SIR class C–E) did not differ between treatment arms ($P=.55$ and $P=.71$, respectively) (Table 1). The AEs are described in detail in Table 3. Most AEs (42; 86%) required only observation or nominal treatment, and none led to permanent adverse sequelae (class E) or death (class F). Two patients in the MRgFUS arm underwent second procedures within the first 6 weeks, 1 electing UAE and 1 choosing hysterectomy; both were deemed to have had incomplete MRgFUS treatment. Three patients in the UAE arm required readmission to the hospital for severe pain, which was associated with postembolization syndrome in 2. Only 8 AEs qualified for reporting using the American College of Obstetricians and Gynecologists classification.

Multivariable Analysis

UAE treatment was significantly associated with a higher likelihood of opioid use and longer time to return to work and normal activities (all $P<.001$), even after adjusting for baseline pain levels and fibroid load using multivariable analysis (Table 4). After adjusting for treatment group and fibroid load, women with higher baseline VAS scores were more likely to use opioid medication ($P=.001$), experience an AE ($P=.01$), and take longer to return to work and normal activities (both $P=.001$) (Table 4). Results were similar when restricting analysis to the RCT group, except that the association between VAS score and AEs was attenuated.

Comment

In this study, women undergoing either UAE or MRgFUS were typically able to return to work within 1 to 2 weeks. However, women undergoing MRgFUS had significantly longer treatment times, with about half undergoing 2 sequential days of treatment, and 9% had incomplete treatment. Substantial differences in recovery trajectory were also observed between treatment groups, with women undergoing MRgFUS reporting lower levels of immediate postprocedure pain, using fewer outpatient pain medications, and fully returning to work sooner than patients undergoing UAE. These differences in recovery parameters persisted even with adjustments for 2 key confounders—baseline pain and fibroid load—both of which were different between treatment arms despite similar uterine volumes, the parameter on which randomization strata was predicated.

Although these differences may be due to chance, it is notable that more women in our RCT declined to proceed with treatment after random assignment to UAE. This is particularly relevant when women declining randomization but consenting to be in an observational cohort chose the 2 procedures in more equal numbers. We suspect that this occurred because women were specifically seeking MRgFUS, which was less likely to be covered by

insurance and was supported within the confines of the RCT. This possible subversion of the allocation process on the part of participants also supports the use of a CCD analysis.

These results on postprocedural recovery are consistent with previous case series and with differences in the mechanism of tissue destruction between UAE and MRgFUS (25–27). UAE is a uterine-directed therapy, in which specific fibroids are not targeted for treatment; in contrast, MRgFUS, like myomectomy, is a fibroid-specific therapy (27). Thus, UAE may result in increased volume of devascularized tissue. In addition, UAE works via ischemic necrosis, whereas MRgFUS induces coagulative necrosis, which may account for differences in pain. It will be important to ascertain whether these differences correlate with long-term outcomes of these therapies.

It is worth noting that both UAE and MRgFUS have substantially shorter recovery times than hysterectomy (28). Although minimally invasive hysterectomies and enhanced recovery protocols have decreased inpatient stays considerably, most women undergoing hysterectomy still stay longer than 1 inpatient day (29,30). Differences are magnified when comparing time to return to work. In our study, MRgFUS and UAE patients returned to work a median of 4 and 8 days after treatment, respectively. In contrast, recent studies of hysterectomy report average time to return to work of 3.8 weeks for laparoscopic-assisted vaginal hysterectomy and 5.9 weeks for total abdominal hysterectomy (31). The loss of productivity while convalescing from traditional surgical approaches for uterine fibroids can be a major economic burden for women and their employers; thus, minimally invasive alternatives to hysterectomy could have substantial benefits.

Our findings also highlight the importance of assessing baseline pain levels, since greater pain was found to be an independent risk factor for prolonged recovery and AEs. Chronic pain after hysterectomy has been reported in up to 32% of women, and studies have shown that preoperative pain predicts postoperative pain (32). Although some studies have linked chronic pelvic pain to higher cumulative rates of hysterectomy, our study is the first to link preoperative pain to the incidence of AEs (33). Further research is needed comparing hysterectomy with minimally invasive options in women with chronic pelvic pain to assess the preferred treatment for this population.

Strengths of our study include implementing a standardized treatment protocol and providing patients in both treatment groups with the same postprocedure instructions and prescriptions. Comparing the recovery trajectory for UAE and MRgFUS treatments is an important and understudied research area. An RCT offers the highest level of evidence, and our study offers the added benefit of increased power and generalizability gained by including similar nonrandomized patients in a parallel cohort via a CCD analysis.

Our study has several important limitations. We could not recruit as many participants as we wanted; thus, some analyses may be underpowered, such as assessment of safety parameters. Some group differences were also present at baseline; although we controlled for these differences using statistical analysis, a larger sample size may have made that unnecessary. The only blinded study aspect was the analysis of postprocedural imaging. In addition, the system used for MRgFUS in this study (ExAblate 2000) is older than that currently used

(ExAblate 2100), and thus the completeness of the treatment and the NPV seen in this study may be lower than those currently achieved. Finally, a key limitation of our study is the small number of black women who were enrolled, despite having a study site devoted specifically to black women and key outreach measures at other sites. Understanding how to optimize recruitment of black women to fibroid RCTs is an important research goal. Other than this limitation, we recruited a representative cohort with significant symptomatic burden based on validated measures and consistent with other studies.

The critical question for these therapies, however, is whether there are differences in long-term outcomes. Long-term studies evaluating comparative effectiveness for symptom relief, economic utilization, and ovarian reserve after treatment will be forthcoming from the FIRSTT study. This will be beneficial information to empower women and their physicians to choose the correct treatment for uterine fibroids and improve overall quality of life on an individual basis.

Acknowledgments

Source of Funding: Supported by RC1HD063312 and R01HD060503 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health and NIH/NCRR CTSA Grant Number UL1 RR024150. InSightec (Tirat Carmel, Israel) provided support for payment of treatment costs for some study participants but had no role in study design or conduct and review of data, abstracts, or manuscript. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Clinical Trial Registration Number: NCT00995878, clinicaltrials.gov.

E.A.S. reports consulting from AbbVie, Allergan, Bayer, Gynesonics, Astellas, and Viteava Pharmaceuticals related to uterine fibroids; Welltigs related to infertility; and GlaxoSmithKline related to adenomyosis. G.K.H., K.R.G., T.M.P., and A.N. report grants from InSightec outside the submitted work. A.M.A. reports fellowship funding from the Egyptian Ministry of Higher Education and Scientific Research. P.C.L. reports grants from BioSpecifics Technologies Corp outside the submitted work and a patent pending (Treatment Method and Product for Uterine Fibroids using Purified Collagenase). V.L.J. reports grants from Halt Medical outside the submitted work.

Abbreviations

AE	adverse event
CCD	comprehensive cohort design
FIRSTT	Fibroid Interventions: Reducing Symptoms Today and Tomorrow
IQR	interquartile range
MRgFUS	magnetic resonance imaging–guided focused ultrasound surgery
NPV	nonperfused volume
PC1	parallel cohort 1
RCT	randomized controlled trial
SIR	Society of Interventional Radiology
UAE	uterine artery embolization
UFS-QOL	Uterine Fibroid Symptom and Quality of Life

VAS visual analog scale for pain

References

1. Gliklich, RE., Leavy, MB., Velentgas, P., Campion, DM., Mohr, P., Sabharwal, R., et al. Effective Health Care Program Research Report No.31. Rockville (MD): Agency for Healthcare Research and Quality; 2011 Mar. Identification of future research needs in the comparative management of uterine fibroid disease: a report on the priority-setting process, preliminary data analysis, and research plan.
2. Pinto I, Chimenó P, Romo A, Paul L, Haya J, de la Cal MA, et al. Uterine fibroids: uterine artery embolization versus abdominal hysterectomy for treatment: a prospective, randomized, and controlled clinical trial. *Radiology*. 2003 Feb; 226(2):425–431. [PubMed: 12563136]
3. Mara M, Fucikova Z, Maskova J, Kuzel D, Haakova L. Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial. *Eur J Obstet Gynecol Reprod Biol*. 2006 Jun 1; 126(2):226–233. Epub 2005 Nov 15. [PubMed: 16293363]
4. Edwards RD, Moss JG, Lumsden MA, Wu O, Murray LS, Twaddle S, et al. Committee of the Randomized Trial of Embolization versus Surgical Treatment for Fibroids. Uterine-artery embolization versus surgery for symptomatic uterine fibroids. *N Engl J Med*. 2007 Jan 25; 356(4): 360–370. [PubMed: 17251532]
5. Levens ED, Potlog-Nahari C, Armstrong AY, Wesley R, Premkumar A, Blithe DL, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. *Obstet Gynecol*. 2008 May; 111(5):1129–1136. [PubMed: 18448745]
6. Hald K, Noreng HJ, Istre O, Klow NE. Uterine artery embolization versus laparoscopic occlusion of uterine arteries for leiomyomas: long-term results of a randomized comparative trial. *J Vasc Interv Radiol*. 2009 Oct; 20(10):1303–1310. Epub 2009 Aug 26. [PubMed: 19713130]
7. van der Kooij SM, Hehenkamp WJ, Volkers NA, Birmie E, Ankum WM, Reekers JA. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 5-year outcome from the randomized EMMY trial. *Am J Obstet Gynecol*. 2010 Aug; 203(2):105.e1–105.e13. Epub 2010 Jul 1. [PubMed: 20579960]
8. Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. *Fertil Steril*. 2010 Jan; 93(1):192–198. Epub 2009 Jan 9. [PubMed: 19135657]
9. Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. *Int J Gynaecol Obstet*. 2011 Feb; 112(2):126–130. Epub 2010 Nov 19. [PubMed: 21092958]
10. Wang X, Qin J, Wang L, Chen J, Chen W, Tang L. Effect of high-intensity focused ultrasound on sexual function in the treatment of uterine fibroids: comparison to conventional myomectomy. *Arch Gynecol Obstet*. 2013 Oct; 288(4):851–858. Epub 2013 Apr 7. [PubMed: 23564052]
11. Dickersin K, Munro M, Langenberg P, Scherer R, Frick KD, Weber AM, et al. Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding Research Group. Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB): design and methods. *Control Clin Trials*. 2003 Oct; 24(5):591–609. [PubMed: 14500057]
12. Varner RE, Ireland CC, Summitt RL Jr, Richter HE, Learman LA, Vittinghoff E, et al. Ms Research Group. Medicine or Surgery (Ms): a randomized clinical trial comparing hysterectomy and medical treatment in premenopausal women with abnormal uterine bleeding. *Control Clin Trials*. 2004 Feb; 25(1):104–118. [PubMed: 14980755]
13. Dickersin K, Munro MG, Clark M, Langenberg P, Scherer R, Frick K, et al. Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Research Group. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. *Obstet Gynecol*. 2007 Dec; 110(6):1279–1289. Erratum in: *Obstet Gynecol*. 2008 Aug; 112(2 Pt 1):381. [PubMed: 18055721]

14. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. *Obstet Gynecol.* 2010 Oct; 116(4):865–875. [PubMed: 20859150]
15. Bouwsma EV, Hesley GK, Woodrum DA, Weaver AL, Leppert PC, Peterson LG, et al. Comparing focused ultrasound and uterine artery embolization for uterine fibroids: rationale and design of the Fibroid Interventions: Reducing Symptoms Today and Tomorrow (FIRSTT) trial. *Fertil Steril.* 2011 Sep; 96(3):704–710. Epub 2011 Jul 27. [PubMed: 21794858]
16. Abdelmagied AM, Vaughan LE, Weaver AL, Laughlin-Tommaso SK, Hesley GK, Woodrum DA, et al. Fibroid interventions: reducing symptoms today and tomorrow: extending generalizability by using a comprehensive cohort design with a randomized controlled trial. *Am J Obstet Gynecol.* 2016 Sep; 215(3):338.e1–338.e18. Epub 2016 Apr 9. [PubMed: 27073063]
17. Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD. Systematic review to determine whether participation in a trial influences outcome. *BMJ.* 2005 May 21; 330(7501):1175. [PubMed: 15905256]
18. Spies JB, Coyne K, Guaou N, Boyle D, Skrynarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. *Obstet Gynecol.* 2002 Feb; 99(2):290–300. [PubMed: 11814511]
19. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. *Biometrics.* 1975 Mar; 31(1):103–115. [PubMed: 1100130]
20. Goodwin SC, Spies JB. Uterine fibroid embolization. *N Engl J Med.* 2009 Aug 13; 361(7):690–697. [PubMed: 19675331]
21. Gorny KR, Woodrum DA, Brown DL, Henrichsen TL, Weaver AL, Amrami KK, et al. Magnetic resonance-guided focused ultrasound of uterine leiomyomas: review of a 12-month outcome of 130 clinical patients. *J Vasc Interv Radiol.* 2011 Jun; 22(6):857–864. Epub 2011 Apr 8. [PubMed: 21482137]
22. Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. Complications after uterine artery embolization for leiomyomas. *Obstet Gynecol.* 2002 Nov; 100(5 Pt 1):873–880. [PubMed: 12423844]
23. American College of Obstetricians and Gynecologists. Quality assessment and improvement in obstetrics and gynecology. Washington (DC): American College of Obstetricians and Gynecologists; 1994. p. 16
24. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. *Am J Epidemiol.* 2003 May 15; 157(10):940–943. [PubMed: 12746247]
25. Goodwin SC, Spies JB, Worthington-Kirsch R, Peterson E, Pron G, Li S, et al. Fibroid Registry for Outcomes Data (FIBROID) Registry Steering Committee and Core Site Investigators. Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. *Obstet Gynecol.* 2008 Jan; 111(1):22–33. [PubMed: 18165389]
26. Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. *Fertil Steril.* 2006 Jan; 85(1):22–29. Erratum in: *Fertil Steril.* 2006 Apr; 85(4):1072. [PubMed: 16412721]
27. Stewart EA. Clinical practice. Uterine fibroids. *N Engl J Med.* 2015 Apr 23; 372(17):1646–1655. [PubMed: 25901428]
28. Fergusson RJ, Lethaby A, Shepperd S, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. *Cochrane Database Syst Rev.* 2013 Nov 29. (11):CD000329. [PubMed: 24288154]
29. Kongwattanakul K, Khampitak K. Comparison of laparoscopically assisted vaginal hysterectomy and abdominal hysterectomy: a randomized controlled trial. *J Minim Invasive Gynecol.* 2012 Jan-Feb; 19(1):89–94. Epub 2011 Nov 30. [PubMed: 22133703]
30. Miller EC, McIsaac DI, Chaput A, Antrobus J, Shenassa H, Lui A. Increased postoperative day one discharges after implementation of a hysterectomy enhanced recovery pathway: a retrospective cohort study. *Can J Anaesth.* 2015 May; 62(5):451–460. Epub 2015 Feb 28. [PubMed: 25724789]

31. Lenihan JP Jr, Kovanda C, Cammarano C. Comparison of laparoscopic-assisted vaginal hysterectomy with traditional hysterectomy for cost-effectiveness to employers. *Am J Obstet Gynecol.* 2004 Jun; 190(6):1714–1720. [PubMed: 15284779]
32. Brandsborg B, Dueholm M, Nikolajsen L, Kehlet H, Jensen TS. A prospective study of risk factors for pain persisting 4 months after hysterectomy. *Clin J Pain.* 2009 May; 25(4):263–268. [PubMed: 19590472]
33. Learman LA, Kuppermann M, Gates E, Gregorich SE, Lewis J, Washington AE. Predictors of hysterectomy in women with common pelvic problems: a uterine survival analysis. *J Am Coll Surg.* 2007 Apr; 204(4):633–641. Epub 2007 Feb 23. [PubMed: 17382223]

Figure.

Flow Diagram for the Selection, Enrollment, and Randomization of the Participants in a Comprehensive Cohort Design. Solid lines and unshaded boxes show disposition of randomized controlled trial participants. Dashed lines and shaded boxes indicate flow of participants who entered parallel cohort 1 (PC1) or were excluded by screening. GnRH, indicates gonadotropin-releasing hormone; MRgFUS, magnetic resonance imaging–guided ultrasound surgery; MRI, magnetic resonance imaging; UAE, uterine artery embolization. ^aEleven patients had 2 exclusion criteria. (Adapted from AbdElmagied et al [16]. Used with permission.)

Table 1
Baseline Characteristics, Day-of-Treatment Measures, and Adverse Events of Treated Study Participants

Characteristic	RCT			CCD		
	MRgFUS (n=27)	UAE (n=22)	P Value	MRgFUS (n=43)	UAE (n=40)	P Value
Demographic data						
Age at treatment, y, mean (SD)	44.0 (4.3)	44.3 (5.2)	.84	44.0 (5.0)	44.9 (5.0)	.45
Race, n (%)			.22			.41
White	18 (67)	18 (82)		28 (65)	31 (78)	
Black	3 (11)	4 (18)		5 (12)	4 (10)	
Asian	1 (4)	0 (0)		4 (9)	1 (3)	
Hispanic or Latina	3 (11)	0 (0)		4 (9)	1 (3)	
Other	2 (7)	0 (0)		2 (5)	3 (8)	
BMI, kg/m ² , mean (SD)	27.4 (5.7)	30.1 (5.1)	.09	26.7 (5.5)	27.8 (6.4)	.41
Age at fibroid diagnosis, y, mean (SD)	39.6 (7.2)	39.5 (7.8)	.97	39.9 (7.1)	40.9 (7.1)	.49
Uterine characteristics						
Number of fibroids 3 cm, n (%)			.17			.17
0	2 (7)	1 (5)		2 (5)	1 (3)	
1	11 (41)	13 (59)		18 (42)	21 (53)	
2	1 (4)	5 (23)		4 (9)	11 (28)	
3	8 (30)	1 (5)		11 (26)	3 (8)	
4	5 (19)	2 (9)		8 (19)	4 (10)	
Calculated uterine volume, cm ³ , median (IQR)	549 (334–693)	540 (402–690)	.82	586 (395–707)	540 (382–837)	.90
Total fibroid load, cc ³ , mean (SD) ^a	225.0 (125.1)	365.4 (233.2)	.01	249.2 (159.9)	362.5 (292.3)	.03
Baseline validated measures						
MPQ total score, median (IQR)	11.0 (6.0–20.0)	7.5 (3.0–16.0)	.19	10.0 (6.0–17.0)	7.0 (2.0–12.0)	.08
VAS pain score, median (IQR) ^b	48.0 (27.0–71.0)	27.0 (5.0–52.0)	.03	38.0 (21.0–66.0)	24.5 (4.5–54.0)	.08

Characteristic	RCT			CCD		
	MRgFUS (n=27)	UAE (n=22)	P Value	MRgFUS (n=43)	UAE (n=40)	P Value
UFSQOL						
Symptom Severity Score, mean (SD)	54.6 (21.6)	53.0 (17.7)	.79	53.9 (19.8)	53.1 (19.8)	.85
Health-related quality of life, mean (SD)	50.6 (19.2)	51.7 (19.3)	.85	52.5 (18.4)	51.0 (23.0)	.76
Day-of-treatment measures						
Total treatment time, min, mean (SD) ^c	390 (138)	137 (47)	<.001	405 (146)	139 (44)	<.001
Pain rating, median (IQR) ^d						
On arrival to recovery area	3.0 (1.0–5.0)	5.0 (1.0–7.0)	.14	1.0 (1.0–4.0)	5.0 (1.0–7.0)	.002
On discharge from recovery area	2.0 (1.0–4.0)	3.0 (2.0–5.0)	.16	1.0 (1.0–4.0)	4.0 (2.0–6.0)	<.001
Adverse events, n (%)						
Any	12 (44)	9 (41)	.80	20 (47)	16 (40)	.55
Any SIR class C–E	2 (7)	2 (9)	>.99	3 (7)	4 (10)	.71

Abbreviations: BMI, body mass index; CCD, comprehensive cohort design; IQR, interquartile range; MPQ, McGill Pain Questionnaire; MRgFUS, magnetic resonance imaging–guided ultrasound surgery; RCT, randomized controlled trial; SD, standard deviation; SIR, Society of Interventional Radiology; UAE, uterine artery embolization; UFSQOL, Uterine Fibroid Symptom and Quality of Life questionnaire; VAS, visual analog scale.

^aTotal fibroid load calculated based on all fibroids >1 cm.

^bScale of 0, no pain, to 100, worst pain possible.

^cTotal treatment time was calculated using both days of treatment, when applicable.

^dScale of 0, no pain, to 10, worst pain possible.

Table 2

6-Week Postoperative Measures of Disability of Treated Patients

Measure	RCT (n=45)			CCD (n=75)		
	MRgFUS (n=25)	UAE (n=20)	P Value	MRgFUS (n=39)	UAE (n=36)	P Value
Outpatient medication use						
Any use, n (%)						
Opioids	6 (24)	14 (70)	.002	8 (21)	27 (75)	<.001
NSAIDs	17 (68)	19 (95)	.02	26 (67)	35 (97)	<.001
Tylenol/aspirin	16 (64)	6 (30)	.02	23 (59)	14 (39)	.08
Nausea medication	3 (12)	8 (40)	.03	3 (8)	16 (44)	<.001
Bowel medication	8 (32)	17 (85)	<.001	11 (28)	29 (81)	<.001
Alt/Comp medication	10 (40)	11 (55)	.32	13 (33)	19 (53)	.09
Total days used among users, median (IQR)						
Opioids	9 (2–40)	3 (2–5)	.23	4 (2–26)	2 (2–4)	.43
NSAIDs	8 (3–19)	10 (7–13)	.68	7 (2–19)	9 (6–13)	.58
Tylenol/aspirin	5 (3–9)	3 (2–6)	.39	5 (3–9)	3 (2–6)	.23
Alt/Comp medications	7 (2–24)	3 (1–13)	.64	10 (2–24)	6 (2–13)	.63
Day of last use among users, median (IQR)						
Opioids	37 (5–42)	3 (2–5)	.049	27 (4–41)	3 (2–5)	.03
NSAIDs	32 (18–37)	14 (9–40)	.29	32 (19–38)	13 (6–36)	.04
Tylenol/aspirin	16 (5–31)	4 (2–6)	.03	18 (5–36)	3 (2–6)	.004
Return to normal activities, median (IQR)						
First day back to work	5 (3–8)	8 (5–14)	.08	4 (2–7)	8 (6–14)	<.001
First day totally back to normal	11 (10–16)	15 (10–24)	.23	10 (10–15)	15 (10–29)	.02
Other reported symptoms, n (%)						
Fatigue	20 (80)	17 (85)	.72	33 (85)	31 (86)	.86
Hot flashes	11 (44)	11 (55)	.46	15 (38)	18 (50)	.32
Fever	3 (12)	4 (20)	.68	4 (10)	9 (25)	.09

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Measure	RCT (n=45)			CCD (n=75)		
	MRgFUS (n=25)	UAE (n=20)	P Value	MRgFUS (n=39)	UAE (n=36)	P Value
Discomfort urinating	12 (48)	11 (55)	.64	18 (46)	19 (53)	.57
Passage of fibroid tissue	10 (40)	10 (50)	.50	19 (49)	17 (47)	.90
Vaginal discharge	16 (64)	16 (80)	.24	27 (69)	26 (72)	.78
Constipation	18 (72)	16 (80)	.73	28 (72)	28 (78)	.55
Diarrhea	8 (32)	10 (50)	.22	12 (31)	18 (50)	.09

Abbreviations: Alt/Comp, alternative/complementary; CCD, comprehensive cohort design; IQR, interquartile range; MRgFUS, magnetic resonance imaging—guided ultrasound surgery; NSAID, nonsteroidal anti-inflammatory drug; RCT, randomized controlled trial; UAE, uterine artery embolization.

Table 3

Number of AEs by SIR Class for All Patients in the CCD

SIR Class and AE Category^a	MRgFUS (n=43)	UAE (n=40)
Class D (major therapy, unplanned increase in level of care, prolonged hospitalization)	2	2
Surgical treatment within 6 wk	2	0
Rehospitalization (> 48 h)	0	1
Postembolization syndrome	0	1
Class C (required therapy, minor hospitalization)	1	2
Rehospitalization (<48 h)	0	2
Other: urinary retention requiring catheterization	1	0
Class B (nominal therapy, observation, no consequences)	11	13
Postembolization syndrome	0	2
Severe/prolonged pain	3	1
Vaginal passage of leiomyoma tissue	1	3
Peripheral nerve injury: sacral neuropathy	2	0
Urinary tract infection	3	1
Allergic reaction/rash	1	2
Other	1	4
Class A (no therapy, no consequences)	13	5
Severe/prolonged pain	2	0
Vaginal passage of leiomyoma tissue	1	0
Peripheral nerve injury	3	0
Upper/lower extremity tingling	2	
Sacral neuropathy	1	
Urinary tract infection	1	0
Allergic reaction/rash	2	0
Other	4	5

Abbreviations: AE, adverse event; CCD, comprehensive cohort design; MRgFUS, magnetic resonance imaging–guided ultrasound surgery; SIR, Society of Interventional Radiology; UAE, uterine artery embolization.

^aNo AEs of class F (death) or E (permanent adverse sequelae) occurred in the CCD cohort.

Table 4

Multivariable Analysis of Treatment and Recovery Parameters

Outcome	Predictor ^a	RCT			CCD		
		Adjusted RR/OR/Mean ^b	95% CI	P Value	Adjusted RR/OR/Mean ^b	95% CI	P Value
Binary outcomes							
Opioid use ^c	UAE	4.28	1.94–9.42	<.001	4.57	2.51–8.33	<.001
	VAS score	1.14	1.03–1.28	.02	1.12	1.05–1.20	.001
	Fibroid load	1.01	0.80–1.29	.93	1.02	0.89–1.18	.74
Any AE ^c	UAE	1.22	0.59–2.51	.59	0.99	0.58–1.70	.96
	VAS score	1.11	0.98–1.25	.10	1.12	1.03–1.23	.01
	Fibroid load	0.93	0.69–1.25	.64	0.94	0.76–1.17	.59
AE SIR class C–E ^d	UAE	1.40	0.11–17.48	.80	0.87	0.10–7.48	.90
	VAS score	1.42	0.89–2.27	.15	1.55	1.05–2.29	.03
	Fibroid load	2.30	0.54–9.84	.26	2.76	0.89–8.62	.08
Continuous outcomes ^e							
1st Day fully back to work	UAE	2.01	1.28–3.14	.004	2.13	1.51–2.99	<.001
	VAS score	1.24	1.15–1.34	<.001	1.18	1.11–1.25	<.001
	Fibroid load	1.04	0.88–1.23	.64	1.07	0.94–1.22	.30
1st Day totally back to normal	UAE	2.71	1.49–4.93	.002	2.50	1.59–3.93	<.001
	VAS score	1.23	1.11–1.36	<.001	1.15	1.06–1.24	.001
	Fibroid load	1.02	0.82–1.28	.84	1.04	0.87–1.23	.67

Abbreviations: AE, adverse event; CCD, comprehensive cohort design; CI, confidence interval; MRgFUS, magnetic resonance imaging–guided ultrasound surgery; OR, odds ratio; RCT, randomized controlled trial; RR, risk ratio; SIR, Society of Interventional Radiology; UAE, uterine artery embolization; VAS, visual analog scale for pain.

^a All predictors measured at baseline.

^b For UAE, MRgFUS is the reference treatment group. For VAS score, value is per 10-unit increase in baseline pain on a scale of 0, no pain, to 100, worst pain possible. For fibroid load, value is per doubling of fibroid load in cc³.

^c Values are adjusted RRs.

^d Values are adjusted ORs.

Values are adjusted means.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript